Antibiotics API Raw Materials Amikacin disulfate salt Powder

CAS:39831-55-5

MF: C22H45N5O17S

MW: 683.68

EINECS:254-648-6

Specification​: 99% min Amikacin disulfate salt Powder

Sample: Amikacin disulfate salt Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Amikacin disulfate salt Usage and Synthesis.

Amikacin sulphate is commonly used in preparations such as injections. For aminoglycoside antibiotics.

It is used for serious infections caused by Pseudomonas aeruginosa and some other pseudomonas, Escherichia coli, Aspergillus spp., Klebsiella spp. and other sensitive gram-negative bacilli and staphylococcus spp. such as bacteraemia or sepsis, bacterial endocarditis, lower respiratory tract infections, bone and joint infections, biliary tract infections and so on.

As the product is stable to most aminoglycoside blunting enzymes, it is also used to treat serious infections caused by Gram-negative bacilli resistant to kanamycin, gentamicin or tobramycin.

Uses and functions of Amikacin disulfate salt.

Amikacin sulphate is an anti-infective drug used for the treatment of urinary tract infections, sepsis, skin infections, bone and joint infections, pneumonia and lower respiratory tract infections caused by sensitive bacteria.

Amikacin Sulfate is used for serious infections caused by sensitive gram-negative bacilli and staphylococci of Pseudomonas aeruginosa and some other pseudomonas, Escherichia coli, Proteus spp. and Klebsiella spp. such as bacteraemia or sepsis, bacterial endocarditis, lower respiratory tract infections, bone and joint infections, biliary tract infections and so on.

Amikacin sulphate is also used for the treatment of serious infections caused by Gram-negative bacilli resistant to kanamycin, gentamicin or tobramycin, as it is stable to most aminoglycoside obturators.

Pharmacological Effects of Amikacin disulfate salt.

1, Amikacin sulphate is a kind of aminoglycoside antibiotic, on most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Enterobacter, Aspergillus, Shigella, Salmonella, Citrobacter, Serratia and so on have a good effect, on Pseudomonas aeruginosa and other Pseudomonas, Bacillus sp., alkali bacillus, and so on also have a good effect;

Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Yersinia pestis, Campylobacter fetus, Mycobacterium tuberculosis and some non-tuberculosis Mycobacterium spp. also have good antibacterial effect, its antibacterial activity is slightly lower than gentamicin.

The most outstanding advantage of this product is that it is stable to the aminoglycoside passivation enzyme produced by many enteric gram-negative bacilli, and will not be passivated by this kind of enzyme and lose antibacterial activity.

Of the 12 currently isolated passivating enzymes, it is only passivated by AAC (6'), and AAD (4') and APH (3')-III can occasionally lead to moderate bacterial resistance to the product.

About 60%-70% of clinical isolates of Enterobacteriaceae resistant to aminoglycosides such as gentamicin, tobramycin and nertilmicin are still susceptible to this product. In recent years, the number of amikacin-resistant strains of Gram-negative bacilli has also increased.

2, Gram-positive cocci in addition to the staphylococcus genus of methicillin-sensitive strains have good antibacterial effect, Streptococcus pneumoniae, various groups of streptococci and enterococci genus most of the resistance to the drug. It is not effective against anaerobic bacteria.

3, the mechanism of action of this product is to act on the 30S subunit of the bacterial ribosome, inhibiting bacterial protein synthesis. Amikacin and semi-synthetic penicillins or cephalosporins can often be synergistic antibacterial effect.

Drug interactions of  Bulk Amikacin disulfate salt Powder.

1, Amikacin disulfate salt combined with other aminoglycosides or successive sequential local or systemic application, can increase ototoxicity, nephrotoxicity and neuromuscular blocking effect.

2, Amikacin disulfate salt and neuromuscular blocking drugs combined can aggravate the neuromuscular blocking effect, resulting in muscle weakness, respiratory depression and other symptoms.

Amikacin disulfate salt combined with colistin, cisplatin, etanercept, furosemide or vancomycin (or nortriptyline vancomycin), or successive local or systemic applications, may increase ototoxicity and nephrotoxicity.

3, Amikacin disulfate salt and cefotiophene or cefazolin local or systemic combination may increase nephrotoxicity. This product should not be paired with amphotericin B, cefthiophene, sulfadiazine and tetracycline and other injections, not in the same bottle of drip.

4, Amikacin disulfate salt and polymyxin injections in combination or successive successive local or systemic application, may increase nephrotoxicity and neuromuscular blocking effect.

5, other nephrotoxic drugs and ototoxic drugs should not be combined with this product or successive application, so as not to aggravate nephrotoxicity or ototoxicity.